Completed PHASE4 INTERVENTIONAL 1-arm NCT04992208

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents

Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study

Sponsor: Sinovac Life Sciences Co., Ltd.

Conditions COVID-19

Interventions Experimental Group

Updated 7 times since 2021 Last updated: Sep 21, 2023 Started: Jul 24, 2021 Primary completion: Mar 24, 2023 Completion: Aug 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on COVID-19, this trial is completed. The trial is conducted by Sinovac Life Sciences Co., Ltd. and has accumulated 7 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Sep 2023 — Oct 2023 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Sep 2022 — Sep 2023 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Nov 2021 — Sep 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinovac Life Sciences Co., Ltd.

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dali, China